From Proteopedia
(Difference between revisions)
proteopedia linkproteopedia link
|
|
| Line 1: |
Line 1: |
| - | [[Image:2fmb.jpg|left|200px]] | + | {{Seed}} |
| | + | [[Image:2fmb.png|left|200px]] |
| | | | |
| | <!-- | | <!-- |
| Line 9: |
Line 10: |
| | {{STRUCTURE_2fmb| PDB=2fmb | SCENE= }} | | {{STRUCTURE_2fmb| PDB=2fmb | SCENE= }} |
| | | | |
| - | '''EIAV PROTEASE COMPLEXED WITH AN INHIBITOR LP-130'''
| + | ===EIAV PROTEASE COMPLEXED WITH AN INHIBITOR LP-130=== |
| | | | |
| | | | |
| - | ==Overview==
| + | <!-- |
| - | One of the major problems encountered in antiviral therapy against AIDS is the emergence of viral variants that exhibit drug resistance. The sequences of proteases (PRs) from related retroviruses sometimes include, at structurally equivalent positions, amino acids identical to those found in drug-resistant forms of HIV-1 PR. The statine-based inhibitor LP-130 was found to be a universal, nanomolar-range inhibitor against all tested retroviral PRs. We solved the crystal structures of LP-130 in complex with retroviral PRs from HIV-1, feline immunodeficiency virus, and equine infectious anemia virus and compared the structures to determine the differences in the interactions between the inhibitor and the active-site residues of the enzymes. This comparison shows an extraordinary similarity in the binding modes of the inhibitor molecules. The only exceptions are the different conformations of naphthylalanine side chains at the P3/P3' positions, which might be responsible for the variation in the Ki values. These findings indicate that successful inhibition of different retroviral PRs by LP-130 is achieved because this compound can be accommodated without serious conformational differences, despite the variations in the type of residues forming the active-site region. Although strong, specific interactions between the ligand and the enzyme might improve the potency of the inhibitor, the absence of such interactions seems to favor the universality of the compound. Hence, the ability of potential anti-AIDS drugs to inhibit multiple retroviral PRs might indicate their likelihood of not eliciting drug resistance. These studies may also contribute to the development of a small-animal model for preclinical testing of antiviral compounds.
| + | The line below this paragraph, {{ABSTRACT_PUBMED_9827997}}, adds the Publication Abstract to the page |
| | + | (as it appears on PubMed at http://www.pubmed.gov), where 9827997 is the PubMed ID number. |
| | + | --> |
| | + | {{ABSTRACT_PUBMED_9827997}} |
| | | | |
| | ==About this Structure== | | ==About this Structure== |
| Line 33: |
Line 37: |
| | [[Category: Retropepsin]] | | [[Category: Retropepsin]] |
| | [[Category: Retrovirus]] | | [[Category: Retrovirus]] |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 04:03:56 2008'' | + | |
| | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 00:44:51 2008'' |
Revision as of 21:44, 28 July 2008
Template:STRUCTURE 2fmb
EIAV PROTEASE COMPLEXED WITH AN INHIBITOR LP-130
Template:ABSTRACT PUBMED 9827997
About this Structure
2FMB is a Single protein structure of sequence from Equine infectious anemia virus. Full crystallographic information is available from OCA.
Reference
Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV., Kervinen J, Lubkowski J, Zdanov A, Bhatt D, Dunn BM, Hui KY, Powell DJ, Kay J, Wlodawer A, Gustchina A, Protein Sci. 1998 Nov;7(11):2314-23. PMID:9827997
Page seeded by OCA on Tue Jul 29 00:44:51 2008
